News|Videos|November 18, 2026

Zilganersen approval brings new treatment approach for Alexander disease

Key Takeaways

  • Zilganersen (Zanvastro) introduces a disease-modifying treatment approach for Alexander disease, which has historically been managed with supportive therapies.
  • Developmental delays, seizures, muscle weakness, and macrocephaly may suggest Alexander disease in younger children, while older patients may present with swallowing difficulties, ataxia, or autonomic symptoms.
SHOW MORE

Lauren Tochen, MD, of Children's National Hospital, discusses how the first disease-modifying therapy for Alexander disease could change care and diagnosis.

The FDA approval of zilganersen (Zanvastro) represents a change in the treatment landscape for Alexander disease, providing the first disease-modifying therapy for a rare, progressive neurologic disorder historically managed through supportive care alone, according to Lauren Tochen, MD, of Children's National Hospital.

In an interview with Contemporary Pediatrics, Tochen discussed how the approval may influence treatment decisions, why recognizing the different clinical presentations of Alexander disease is increasingly important, and what the milestone means for patients and the broader leukodystrophy community.

Zilganersen, an antisense oligonucleotide targeting glial fibrillary acidic protein (GFAP) messenger RNA, received FDA approval on September 3, 2026, for pediatric and adult patients with Alexander disease. The treatment is administered intrathecally every 12 weeks.

How does zilganersen change Alexander disease management?

Before the approval, treatment options for Alexander disease focused on managing symptoms and maintaining patients' quality of life.

"So, up until now, we really were limited to just symptom-based treatments and therapies for Alexander disease and other similar conditions," Tochen said.

These interventions included antiseizure medications, treatments for muscle tightness, developmental therapies, and nutritional support when necessary.

With the availability of zilganersen, clinicians can now consider a treatment targeting the underlying disease process rather than relying exclusively on symptom management.

Tochen explained that earlier intervention may help reduce the need for certain supportive treatments, although the extent of that benefit remains to be established.

"The hope with a disease-modifying therapy is that if we can treat early, we can hopefully minimize the need for some of those other supportive therapies," she said.

However, disease-modifying treatment does not eliminate the role of supportive care. Patients who continue to experience seizures, motor impairment, or nutritional difficulties may still require additional interventions alongside zilganersen.

The approval was supported by clinical trial findings demonstrating improvements in gait speed among patients aged 5 years and older and motor function among younger children. Longer-term outcomes remain under investigation.

What symptoms should prompt evaluation for Alexander disease?

Tochen emphasized that Alexander disease can be difficult to recognize because its clinical presentation varies with age.

In younger children, characteristic findings may include developmental difficulties, gait abnormalities, muscle weakness, seizures, and macrocephaly.

These symptoms should prompt consideration of neurologic or genetic evaluation, particularly when multiple findings occur together.

Tochen recommended brain magnetic resonance imaging (MRI) and genetic testing as important components of the diagnostic evaluation.

However, older children, adolescents, and adults may present with a different constellation of symptoms.

Rather than developmental delays or seizures, these patients may experience symptoms associated with brainstem or cerebellar involvement.

Manifestations can include swallowing difficulties, balance problems, ataxia, dizziness, dysautonomia, and chronic vomiting.

Dysautonomia may involve difficulty regulating blood pressure or heart rate.

Tochen noted that patients with these symptoms may initially be evaluated by other specialists before receiving a neurologic or genetic assessment.

Because Alexander disease is exceptionally rare, recognizing these less typical presentations requires maintaining clinical suspicion when symptoms remain unexplained.

Why does earlier recognition matter following approval?

The availability of disease-modifying treatment increases the importance of identifying Alexander disease across its different clinical presentations.

Previously, diagnosis primarily informed symptom management, supportive interventions, and counseling about disease progression.

Now, identifying affected patients may also provide an opportunity to consider disease-specific treatment.

Tochen emphasized that clinicians should remain aware of presentations occurring beyond early childhood to avoid overlooking adolescents and adults who may benefit from specialist evaluation.

The approval also carries broader significance for patients and families affected by Alexander disease.

Tochen described the challenges families have historically faced while watching children experience progressive neurologic deterioration without an approved treatment targeting the disease.

"I think the patient community and the provider community are thrilled to have a disease-specific intervention," she said.

Although the long-term effects of zilganersen will require continued evaluation, its approval provides a new therapeutic option for a condition with substantial unmet medical needs.

Tochen also emphasized the significance of the development for the broader leukodystrophy community, where disease-specific treatments are becoming increasingly available.

For pediatricians, the approval reinforces the importance of recognizing unexplained neurologic symptoms, considering age-dependent presentations, and referring patients for appropriate neurologic and genetic evaluation.

As treatment options expand, timely diagnosis and coordination with specialty care may play a greater role in the long-term management of Alexander disease.

Reference

US Food and Drug Administration. FDA approves first drug to treat Alexander disease. Published September 3, 2026. Accessed November 18, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease


Related to this article